of the North Caucasus
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
русский
english
Site search
Correspondence address
310 Mira Street, Stavropol, Russia, 355017
Tel
+7 865 2352511, +7 865 2353229.
E-mail
medvestnik@stgmu.ru
The journal is included into The list of leading scientific periodicals.
The journal is included into VINITI database and is registered in Electronic scientific library.
The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.
Prognostic significance of pharmacologically induced hypothyroidism in metastatic renal cancer
[Abstracts]
Adelya Iskalieva; Vyacheslav Ganapolsky; Zaur Pachuliya; Ruslan Glushakov;
The study was held to evaluate the impact of hypothyroidism on the clinical course of metastatic renal cancer. The study included 67 patients with a verified diagnosis of clear cell renal cancer who received specialized antitumor therapy. The thyroid status was assessed prior to and after the respective treatment; the median follow-up period was 24.7 months. Patients who developed hypothyroidism, had their median overall survival rate significantly above that of those with normothyroidism (p=0.004). The one-year survival rate, too, proved to be higher in the hypothyroidism group (p=0.009). Given the above, the development of hypothyroidism could be considered an independent predictor of a favorable prognosis.
References:
1. Состояние онкологической помощи населению России в 2024 году / под ред. Каприна А. Д., Старинского В. В., Шахзадовой А. О. Москва, 2025. [Sostoyaniye onkologicheskoy pomoshchi naseleniyu Rossii v 2024 godu / pod red. Kaprina A. D., Starinskogo V. V., Shakhzadovoy A. O. Moskva, 2025. (In Russ.)].
2. Wang Z., Wang H., Bu C., Meng B., Mu Y. [et al.]. Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications. Eur. J. Сlin. Рharmacol.
2024;80(6):827-838. https://doi.org/10.1007/s00228-024-03626-4
3. Глушаков Р. И., Козырко Е. В., Соболев И. В., Ермолова С. А., Власьева О. В. [и др.]. Заболевания щитовидной железы и риск возникновения нетиреоидной патологии. Казанский медицинский журнал. 2017;98(1):77-84. [Glushakov R. I., Kozyrko E. V., Sobolev I. V., Ermolova S. A., Vlasyeva O. V. [и др.]. Thyroid diseases and the risk of nonthyroidal origin. Kazanskii Meditsinskii zhurnal. – Kazan Medical Journal. 2017;98(1):77-84. (In Russ.)]. https://doi.org/10.17750/KMJ2017-77
4. Glinsky G., Hercbergs A., Davis P. J. Thyroid hormones, mitochondria, aging, and cancer. Front. Endocrinol. (Lausanne). 2026;5;16:1682089. https://doi.org/10.3389/fendo.2025.1682089
5. Czarnecka A. M., Matak D., Szymanski L., Czarnecka K. H., Lewicki S. [et al.]. Triiodothyronine regulates cell growth and survival in renal cell cancer. Int. J. Oncol.
2016;49(4):1666-1678. https://doi.org/10.3892/ijo.2016.3668
Keywords: pharmacologically induced hypothyroidism, multikinase inhibitors, immune-mediated complications
Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy